Cargando…
Initiation and maintenance of a Treat-and-Extend regimen for ranibizumab therapy in wet age-related macular degeneration: recommendations from the UK Retinal Outcomes Group
The treatment of neovascular (wet) age-related macular degeneration (AMD) with ranibizumab is now very well established in terms of efficacy and safety. Recent clinical trials and real-world studies have demonstrated the advantages of a Treat-and-Extend (T&E) regimen, and many hospital departmen...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6136415/ https://www.ncbi.nlm.nih.gov/pubmed/30237693 http://dx.doi.org/10.2147/OPTH.S174560 |
_version_ | 1783354996492861440 |
---|---|
author | Amoaku, Winfried Balaskas, Konstantinos Cudrnak, Tomas Downey, Louise Groppe, Markus Mahmood, Sajjad Mehta, Hemal Mohamed, Quresh Mushtaq, Bushra Severn, Philip Vardarinos, Athanasios Yang, Yit Younis, Saad |
author_facet | Amoaku, Winfried Balaskas, Konstantinos Cudrnak, Tomas Downey, Louise Groppe, Markus Mahmood, Sajjad Mehta, Hemal Mohamed, Quresh Mushtaq, Bushra Severn, Philip Vardarinos, Athanasios Yang, Yit Younis, Saad |
author_sort | Amoaku, Winfried |
collection | PubMed |
description | The treatment of neovascular (wet) age-related macular degeneration (AMD) with ranibizumab is now very well established in terms of efficacy and safety. Recent clinical trials and real-world studies have demonstrated the advantages of a Treat-and-Extend (T&E) regimen, and many hospital departments are now in the process of adopting this new regimen in favor of the pro re nata regimen for initiating and continuing ranibizumab therapy for patients with wet AMD. The comprehensive spectrum of issues related to implementation of the regimen is covered qualitatively in ten didactic topics provided by a group of clinicians with direct experience of this regimen in their department. The topics include definition, new and previously treated eyes, management of high-frequency injections, maximum extensions, discontinuing T&E, bilateral cases, clerical, audit, and patient counseling. This article aims to provide a useful resource for the implementation of the T&E regimen. A quantitative summary of the visual outcomes in key publications is also provided in this article. This article should be a valuable resource for staff training. |
format | Online Article Text |
id | pubmed-6136415 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-61364152018-09-20 Initiation and maintenance of a Treat-and-Extend regimen for ranibizumab therapy in wet age-related macular degeneration: recommendations from the UK Retinal Outcomes Group Amoaku, Winfried Balaskas, Konstantinos Cudrnak, Tomas Downey, Louise Groppe, Markus Mahmood, Sajjad Mehta, Hemal Mohamed, Quresh Mushtaq, Bushra Severn, Philip Vardarinos, Athanasios Yang, Yit Younis, Saad Clin Ophthalmol Expert Opinion The treatment of neovascular (wet) age-related macular degeneration (AMD) with ranibizumab is now very well established in terms of efficacy and safety. Recent clinical trials and real-world studies have demonstrated the advantages of a Treat-and-Extend (T&E) regimen, and many hospital departments are now in the process of adopting this new regimen in favor of the pro re nata regimen for initiating and continuing ranibizumab therapy for patients with wet AMD. The comprehensive spectrum of issues related to implementation of the regimen is covered qualitatively in ten didactic topics provided by a group of clinicians with direct experience of this regimen in their department. The topics include definition, new and previously treated eyes, management of high-frequency injections, maximum extensions, discontinuing T&E, bilateral cases, clerical, audit, and patient counseling. This article aims to provide a useful resource for the implementation of the T&E regimen. A quantitative summary of the visual outcomes in key publications is also provided in this article. This article should be a valuable resource for staff training. Dove Medical Press 2018-09-10 /pmc/articles/PMC6136415/ /pubmed/30237693 http://dx.doi.org/10.2147/OPTH.S174560 Text en © 2018 Amoaku et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Expert Opinion Amoaku, Winfried Balaskas, Konstantinos Cudrnak, Tomas Downey, Louise Groppe, Markus Mahmood, Sajjad Mehta, Hemal Mohamed, Quresh Mushtaq, Bushra Severn, Philip Vardarinos, Athanasios Yang, Yit Younis, Saad Initiation and maintenance of a Treat-and-Extend regimen for ranibizumab therapy in wet age-related macular degeneration: recommendations from the UK Retinal Outcomes Group |
title | Initiation and maintenance of a Treat-and-Extend regimen for ranibizumab therapy in wet age-related macular degeneration: recommendations from the UK Retinal Outcomes Group |
title_full | Initiation and maintenance of a Treat-and-Extend regimen for ranibizumab therapy in wet age-related macular degeneration: recommendations from the UK Retinal Outcomes Group |
title_fullStr | Initiation and maintenance of a Treat-and-Extend regimen for ranibizumab therapy in wet age-related macular degeneration: recommendations from the UK Retinal Outcomes Group |
title_full_unstemmed | Initiation and maintenance of a Treat-and-Extend regimen for ranibizumab therapy in wet age-related macular degeneration: recommendations from the UK Retinal Outcomes Group |
title_short | Initiation and maintenance of a Treat-and-Extend regimen for ranibizumab therapy in wet age-related macular degeneration: recommendations from the UK Retinal Outcomes Group |
title_sort | initiation and maintenance of a treat-and-extend regimen for ranibizumab therapy in wet age-related macular degeneration: recommendations from the uk retinal outcomes group |
topic | Expert Opinion |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6136415/ https://www.ncbi.nlm.nih.gov/pubmed/30237693 http://dx.doi.org/10.2147/OPTH.S174560 |
work_keys_str_mv | AT amoakuwinfried initiationandmaintenanceofatreatandextendregimenforranibizumabtherapyinwetagerelatedmaculardegenerationrecommendationsfromtheukretinaloutcomesgroup AT balaskaskonstantinos initiationandmaintenanceofatreatandextendregimenforranibizumabtherapyinwetagerelatedmaculardegenerationrecommendationsfromtheukretinaloutcomesgroup AT cudrnaktomas initiationandmaintenanceofatreatandextendregimenforranibizumabtherapyinwetagerelatedmaculardegenerationrecommendationsfromtheukretinaloutcomesgroup AT downeylouise initiationandmaintenanceofatreatandextendregimenforranibizumabtherapyinwetagerelatedmaculardegenerationrecommendationsfromtheukretinaloutcomesgroup AT groppemarkus initiationandmaintenanceofatreatandextendregimenforranibizumabtherapyinwetagerelatedmaculardegenerationrecommendationsfromtheukretinaloutcomesgroup AT mahmoodsajjad initiationandmaintenanceofatreatandextendregimenforranibizumabtherapyinwetagerelatedmaculardegenerationrecommendationsfromtheukretinaloutcomesgroup AT mehtahemal initiationandmaintenanceofatreatandextendregimenforranibizumabtherapyinwetagerelatedmaculardegenerationrecommendationsfromtheukretinaloutcomesgroup AT mohamedquresh initiationandmaintenanceofatreatandextendregimenforranibizumabtherapyinwetagerelatedmaculardegenerationrecommendationsfromtheukretinaloutcomesgroup AT mushtaqbushra initiationandmaintenanceofatreatandextendregimenforranibizumabtherapyinwetagerelatedmaculardegenerationrecommendationsfromtheukretinaloutcomesgroup AT severnphilip initiationandmaintenanceofatreatandextendregimenforranibizumabtherapyinwetagerelatedmaculardegenerationrecommendationsfromtheukretinaloutcomesgroup AT vardarinosathanasios initiationandmaintenanceofatreatandextendregimenforranibizumabtherapyinwetagerelatedmaculardegenerationrecommendationsfromtheukretinaloutcomesgroup AT yangyit initiationandmaintenanceofatreatandextendregimenforranibizumabtherapyinwetagerelatedmaculardegenerationrecommendationsfromtheukretinaloutcomesgroup AT younissaad initiationandmaintenanceofatreatandextendregimenforranibizumabtherapyinwetagerelatedmaculardegenerationrecommendationsfromtheukretinaloutcomesgroup |